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A novel natural TEM -lactamase with extended-spectrum activity, TEM-138, was identified in a ceftazi-
dime-resistant clinical isolate of Salmonella enterica serovar Infantis. Compared to TEM-1, TEM-138 contains
the following mutations: E104K, N175I, and G238S. The blaTEM-138 gene was located on a 50-kb transferable
plasmid. Expression studies with Escherichia coli revealed efficient ceftazidimase and cefotaximase activities for
TEM-138.
Class A -lactamases are the most widespread enzymes
among gram-negative bacteria. The extensive use of cephalo-
sporins in clinical practice has selected a large number of
natural variants of the parental plasmid-encoded -lactamases
as TEM-1/2 and SHV-1, with an extended-spectrum activity
towards oxyiminocephalosporins such as cefotaxime, ceftazi-
dime, and ceftriaxone and monobactams such as aztreonam
but not to cephamycins or carbapenems (7, 15). These extended-
spectrum -lactamases (ESBLs) are frequently associated with
nosocomial outbreaks (21), with production detected most
commonly in Klebsiella pneumoniae (3, 21) in addition to other
members of the Enterobacteriaceae family (14) and Pseudomo-
nas aeruginosa (5, 23). They arose through mutations that
introduce one or more amino acid substitutions that alter the
configuration or binding characteristics of the active site (7,
13), resulting in an expansion of the substrate range of the
enzymes (G. A. Jacoby and K. Bush website [http://www.lahey
.org/studies/]) (8, 9).
Early studies reported an increasing frequency of nosoco-
mial infections caused by ESBL-producing species in Tunisia,
with a particular prevalence of the SHV-2 type (6, 16). A
recent investigation showed the presence of SHV-2a and
TEM-4 in isolates of Salmonella enterica serotype Mbandaka
from a Tunisian hospital (19). More-recent studies revealed
the involvement of SHV-12- and SHV-2a-encoding plasmids in
outbreaks of Klebsiella pneumoniae in a Tunisian neonatal
ward (4).
Salmonella enterica serovar Infantis CN2310 was isolated
from a stool culture of a patient in the pediatric unit of the
La-Rabta Hospital (Tunisia). MICs for CN2310 (22) indicated
that this strain was resistant (CLSI documents M2-A9 and
M100-S16 [11, 12]) to all -lactams tested except cefoxitin and
imipenem (Table 1) and also to chloramphenicol and tetracy-
cline. Synergies between amoxicillin-clavulanic acid and ex-
panded-spectrum cephalosporins, such as cefotaxime and
ceftazidime, were observed in a double disk diffusion test (22),
suggesting ESBL production.
A 50-kb plasmid DNA (pCN2310) was extracted from S.
enterica CN2310 by the alkaline lysis method (24). Electropo-
ration of the plasmid pCN2310 (200 ng of DNA) into Esche-
richia coli DH10B (Invitrogen/Life Technologies) was carried
out using a Bio-Rad gene pulser apparatus as recommended by
the manufacturer. Transformants were selected by plating on
LB agar plates containing 100 g/ml ampicillin. In addition,
conjugation experiments were carried out in liquid LB medium
with E. coli HB101 as the recipient, as described previously (4).
Transconjugants were selected on LB agar containing ampicil-
lin (100 g/ml) and streptomycin (100 g/ml). The frequency
of conjugational transfer is 0.45  105/donor.
Analytical isoelectric focusing of crude extract of S. enterica
CN2310 and its transconjugants and transformants, performed
as previously described (2), revealed the presence of an iden-
tical -lactamase band of approximately pI 5.8. The E. coli
transformants and transconjugants were resistant to penicillins
and expanded-spectrum cephalosporins but were susceptible
to cefoxitin and imipenem (Table 1). These results confirmed
the plasmid-mediated production of an ESBL enzyme which
exhibits notable activity against ceftazidime and cefotaxime.
Amplification of the blaTEM gene by PCR was carried out
using the plasmid pCN2310 as the template, the primers
TEM-D (5-ATAAAATTCTTGAAGACGAAAG-3) and
TEM-R (5-TTACCAATGCCTTAATCAGTGA-3), and Taq
DNA polymerase (Promega), as described previously (1). The
1,080-bp PCR product was cloned into pGEM-T Easy cloning
vector to yield the recombinant plasmid pGEM-138, which was
used to transform E. coli DH5. pGEM-138 was isolated and
the sequence of the PCR-generated insert was determined on
both strands (25). The complete sequence of the insert re-
vealed an open reading frame that was identical to blaTEM-1
except for three point mutations. The authenticity of this se-
quence was confirmed by sequencing, on both strands, the
blaTEM gene of the original plasmid.
These mutations were reflected in a change of three amino
acids. The mutations consisted of a replacement of the glu-
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tamic acid residue at position 104 (codon GAG) by lysine
(codon AAG), of the asparagine residue at position 175
(codon AAC) by isoleucine (codon ATC), and of the glycine
residue at position 238 (codon GGT) by serine (codon AGT).
TEM-138 is closely related to TEM-15 (18). The same crit-
ical substitutions involved in the extension of the -lactamase
spectrum were present in this enzyme at positions 104 and 238,
but TEM-138 differed from TEM-15 and all other TEM vari-
ants by an Asn-to-Ile change at position 175. TEM-138 differed
also from the cefotaximase TEM-3 by a Lys-to-Gln change at
position 39 (27).
E. coli DH10B/pCN2310 was grown overnight at 37°C in
Trypto-Casein soya broth medium (Sanofi Diagnostics, Pasteur
France) supplemented with cephaloridine, 100 g/ml, resus-
pended in 50 mM sodium phosphate buffer, pH 7.0 (buffer A).
After sonication (45 s on ice) and centrifugation (10,000
rpm for 20 min at 4°C), the supernatant was loaded onto a
Sephadex G-75 column (95 by 2 cm; Pharmacia, Sweden)
equilibrated with buffer A. Eluted fractions were collected and
tested spectrophotometrically for -lactamase activity with 50
M cephaloridine as the substrate at 255 nm. Active fractions
were pooled, dialyzed against 25 mM Tris-HCl buffer at pH 7.5
(buffer B), and then applied to a DEAE-Sepharose anion-
exchange column (10.2 by 1.2 cm), equilibrated with buffer B.
The TEM-138 -lactamase was eluted at 250 mM NaCl and
subsequently dialyzed overnight against buffer A containing
150 mM NaCl. After 98-fold purification, TEM-138 enzyme
was found, with a specific activity of 399 U/mg of proteins. One
unit of enzyme activity was defined as the amount of enzyme
that hydrolyzed 1 mol of cephaloridine per min per mg of
proteins at room temperature. The Michaelis constant (Km)
and the maximal hydrolysis rate (Vmax) were determined with
the partially purified enzyme by a computerized microacidim-
etry assay with buffer A (17).
Kinetic analysis showed that TEM-138 was able to hydrolyze
ceftazidime and cefotaxime with a relative efficiency similar to
that for benzylpenicillin. The kinetic parameters (Km and
Vmax) of the enzyme are compared to those of TEM-1, TEM-3
(22), and TEM-15 (20) are in Table 2. The TEM-138 -lacta-
mase had a lower Km for ceftazidime than TEM-3 and TEM-15
-lactamases. However, the Km values of the TEM-138 enzyme
were higher for benzylpenicillin, cephaloridine, and cefotaxime
than those of TEM-3. The 50% inhibitory concentration values
of clavulanic acid for TEM-138, TEM-1, and TEM-3 were
0.8 0.06, 0.08, and 0.6 M, respectively (26). The presence of
the Glu104Lys and Gly238Ser mutations induces a lower inhi-
bition efficiency of clavulanic acid (26). In addition, the 50%
inhibitory concentration values of sulbactam increased for
TEM-138 (80  9.7 M) compared to TEM-1 (10 M).
The Asn175Ile substitution, not previously detected in other
TEM-type variants, might be involved in the high affinity of the
TEM-138 enzyme for ceftazidime. Structural characterization
of the enzyme will be interesting to clarify the role of this
mutation.
This report extends the list of ESBLs produced by S. enterica
serovar Infantis, one of the two major serotypes of nontyphoi-
dal Salmonella. The increasing number of Salmonella serotypes
involved in ESBL production, the variety of the ESBLs, the
high stability of the genetic determinants, and the cotransfer of
resistance to antibiotics recommended for the treatment of
systemic nontyphoidal Salmonella infection and typhoid fever
are serious problems, especially in developing countries where
these infections are still endemic (1, 10).
Nucleotide sequence accession number. The nucleotide se-
quence determined in this work was submitted to the GenBank
database and assigned accession number AY853593.
TABLE 1. MICs of various antimicrobial agents for the clinical
isolate S. enterica serovar Infantis CN2310, its transconjugants
and transformants, and E. coli recipients
Antibiotic
MIC for:
S. enterica
serovar
Infantis
CN2310
E. coli
DH10B/
pCN2310 DH10B
CN2310 
HB101a HB101
Ampicillin 	256 128 2 	256 4
Oxacillin 	256 	256 2 	256 
1
Ticarcillin 	256 	256 2 	256 2
Benzylpenicillin 	256 	256 
1 	256 
1
Imipenem 
1 
1 1 2 1
Cephalothin 	256 	256 
1 	256 2
Cephaloridine 	156 	256 1 128 1
Cefotaxime 	256 	256 4 	256 1
Ceftazidime 256 128 1 128 
1
Ceftriaxone 	256 	256 1 	256 
1
Cefuroxime 	256 	256 2 	256 2
Cefpirome 256 256 
1 256 2
Cefoxitin 
1 
1 4 
1 2
Streptomycin 8 2 1 	256 	256
Chloramphenicol 	256 
1 2 
1 
1
Nalidixic acid 16 2 2 2 1
Tetracycline 16 
1 
1 
1 2
a CN2310 conjugated with HB101 as the recipient.
TABLE 2. Kinetic parameters of TEM-1, TEM-3, TEM-15, and TEM-138a
Antibiotic
TEM-1 TEM-3 TEM-15 TEM-138
Km
(M)
Rel Vmax
(%)
Km
(M)
Rel Vmax
(%)
Km
(M)
Rel Vmax
(%)
Km
(M)b
Rel Vmax
(%)
Benzylpenicillin 26 100 3.8 100 6 100 4.9  1.2 100
Ampicillin 40 122 8.2 126 6.8  0.75 108
Cephaloridine 244 25 19 120 32 189 31  6.8 48
Ceftazidime 350 65 257 19 187  32.2 79
Cefotaxime 35 252 59 292 56  11.6 65
a See reference 22 for TEM-1 and TEM-3 and reference 20 for TEM-15. Relative (Rel) Vmax values were obtained by normalizing the value for each antibiotic to
that for benzylpenicillin (taken as 100).
b Standard deviations are from triplicate determinations.
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